Silo Pharma announces its first cryptocurrency purchases, initiating a treasury strategy for blockchain and biopharma development.
Quiver AI Summary
Silo Pharma, Inc. has announced its initial purchases of Ethereum (ETH) and Solana (SOL) tokens as part of a new cryptocurrency treasury strategy aimed at multi-chain asset growth. This initiative marks the company's first foray into cryptocurrency, which they believe will enhance their financial position and support their biopharmaceutical development goals. CEO Eric Weisblum emphasized the company’s confidence in decentralized blockchain technology as a driver for innovation in biotechnology. The acquisition aligns with the growing institutional interest in digital assets and the evolving regulatory landscape that supports market acceptance. Silo Pharma focuses on addressing underserved medical conditions through its innovative therapeutic programs, with ongoing research collaborations with leading academic institutions.
Potential Positives
- Company has initiated cryptocurrency acquisitions, marking a strategic step toward diversifying its financial assets and entering the blockchain space.
- The staking of Ethereum and Solana tokens for revenue generation indicates a proactive approach to enhancing the financial position and supporting clinical developments.
- The alignment with the growing adoption of digital assets by institutional investors reflects a forward-thinking strategy that positions the company well for future market trends.
- Silo Pharma’s focus on innovative biopharmaceutical programs highlights its commitment to addressing significant health issues, potentially attracting interest from investors and partners in the healthcare sector.
Potential Negatives
- The announcement of a cryptocurrency treasury strategy may signal a diversion of focus from the core biopharmaceutical development initiatives, potentially raising concerns among investors about the company's prioritization and resource allocation.
- The reliance on digital assets and cryptocurrency investments carries inherent volatility and risk, which could jeopardize the financial stability of the company and affect its operations in the biopharmaceutical sector.
- The extensive use of forward-looking statements without guarantee of actual results diminishes investor confidence regarding the company’s ability to meet its projected goals, especially in the context of anticipated revenues and technological development.
FAQ
What did Silo Pharma announce on September 16, 2025?
Silo Pharma announced its initial purchases of cryptocurrency tokens as part of its new cryptocurrency treasury strategy.
Which cryptocurrencies did Silo Pharma acquire?
Silo Pharma acquired Ethereum (ETH) and Solana (SOL) tokens to integrate cryptocurrency into its treasury holdings.
How does Silo Pharma view the future of blockchain technology?
Silo Pharma believes in the long-term value of digital assets and blockchain technology's potential to influence biotechnology.
What is the purpose of Silo's cryptocurrency treasury strategy?
The strategy aims to achieve multi-chain asset growth and enhance financial strength to support biopharmaceutical asset development.
What therapeutic areas does Silo Pharma focus on?
Silo Pharma focuses on treating underserved conditions, including PTSD, chronic pain, and central nervous system diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SILO Insider Trading Activity
$SILO insiders have traded $SILO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SILO stock by insiders over the last 6 months:
- ERIC WEISBLUM (Chief Executive Officer) purchased 10,000 shares for an estimated $4,329
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SILO Hedge Fund Activity
We have seen 8 institutional investors add shares of $SILO stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADVISORSHARES INVESTMENTS LLC added 60,000 shares (+48.3%) to their portfolio in Q2 2025, for an estimated $37,800
- TWO SIGMA SECURITIES, LLC added 43,219 shares (+inf%) to their portfolio in Q2 2025, for an estimated $27,227
- RENAISSANCE TECHNOLOGIES LLC removed 37,500 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $43,875
- URSA FUND MANAGEMENT, LLC added 37,500 shares (+inf%) to their portfolio in Q2 2025, for an estimated $23,625
- XTX TOPCO LTD added 26,823 shares (+inf%) to their portfolio in Q2 2025, for an estimated $16,898
- UBS GROUP AG removed 20,085 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $23,499
- CONNING INC. removed 20,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,600
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Strategic capital deployment advances Company’s blockchain treasury model and biopharma development initiatives
SARASOTA, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchases of crypto tokens under its recently announced cryptocurrency treasury strategy targeting multi-chain asset growth.
The Company’s acquisition of Ethereum (ETH) and Solana (SOL) tokens marks the first step toward incorporating cryptocurrency into its treasury holdings and lays the foundation for Silo’s broader blockchain and real world asset (RWA) tokenization initiatives. The investment underscores the Company’s belief in the long-term value of digital assets and the potential of underlying blockchain technology to shape the future of biotechnology.
“Our initial purchases of Ethereum and Solana reflect our deep conviction in decentralized blockchain and decentralized finance as the leading smart contract platforms,” said Eric Weisblum, CEO of Silo. “We have begun staking the tokens for revenue generation and capital appreciation to further strengthen our financial position and support the clinical progression of our biopharmaceutical assets.”
Silo’s comprehensive digital assets strategy aligns with the accelerating adoption of digital assets by institutional investors and global enterprises, supported by a regulatory landscape that is steadily evolving to enable broader market acceptance
About Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
[email protected]
